- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright reiterates Inhibikase stock rating on trial progress | 2 | Investing.com | ||
| Di | Inhibikase: Erster Patient in Phase-3-Studie für Lungenhochdruck-Medikament aufgenommen | 1 | Investing.com Deutsch | ||
| INHIBIKASE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Di | Inhibikase startet Phase-3-Studie für Lungenhochdruck-Medikament mit erstem Patienten | 2 | Investing.com Deutsch | ||
| Di | Inhibikase enrolls first patient in Phase 3 PAH drug trial | 1 | Investing.com | ||
| Di | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.04. | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 26.03. | Inhibikase Therapeutics GAAP EPS of -$0.49 | 1 | Seeking Alpha | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.03. | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | 253 | GlobeNewswire (Europe) | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| 21.01. | BofA Securities initiates coverage on Inhibikase stock with Buy rating | 6 | Investing.com | ||
| 29.12.25 | Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path | 3 | Investing.com | ||
| 29.12.25 | Jefferies bekräftigt Kaufempfehlung für Inhibikase-Aktie wegen beschleunigtem FDA-Verfahren | 8 | Investing.com Deutsch | ||
| 26.12.25 | Inhibikase: H.C. Wainwright startet Coverage mit "Buy" und 385 % Kurspotenzial | 3 | Investing.com Deutsch | ||
| 26.12.25 | H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating | 3 | Investing.com | ||
| 19.12.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share | 1 | Seeking Alpha | ||
| 21.11.25 | Inhibikase Therapeutics prices $100 million public offering | 1 | Investing.com | ||
| 21.11.25 | Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ABBVIE | 177,50 | +0,06 % | RBC Capital reiterates Abbvie stock Outperform rating at $260 target | ||
| TEVA | 26,100 | -0,76 % | Teva Pharmaceutical Industries Limited (TEVA): Billionaire Stan Druckenmiller Trims Position | ||
| EYEPOINT | 12,100 | 0,00 % | EyePoint, Inc.: EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments | - Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 - - Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME -... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,226 | +2,34 % | Organigram Global Inc.: Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,928 | -2,59 % | Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied | TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 65,28 | -1,21 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen | |
| AMARIN | 12,300 | 0,00 % | Amarin Corporation plc: American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction | ||
| ACHIEVE LIFE SCIENCES | 2,880 | -2,70 % | Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 165,00 | -0,33 % | Prognose massiv erhöht - Wird der australische Psychodelika-Spezialist Bioxyne zum neuen Branchenliebling? | ||
| SELLAS LIFE SCIENCES | 4,100 | +0,99 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 437,50 | -1,31 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| XORTX THERAPEUTICS | 2,085 | -3,18 % | XFRA ANU: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 64,12 | +0,83 % | RBC Capital startet Coverage für BridgeBio Pharma mit "Outperform" und Kursziel 100 US-Dollar | ||
| OPUS GENETICS | 4,560 | 0,00 % | Opus Genetics, Inc.: Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital | - Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage... ► Artikel lesen | |
| RIGEL PHARMACEUTICALS | 26,230 | +5,26 % | Rigel Pharmaceuticals: Warum diese kleine Biotech-Aktie plötzlich kaum zu ignorieren ist | Rigel Pharmaceuticals rückt nach einem Strategiewechsel, einer gestrafften Kostenbasis und einem Portfolio mit mehreren Wachstumstreibern wieder in den Fokus spekulativ orientierter Investoren. Die... ► Artikel lesen |
Das Unternehmen INHIBIKASE THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,005 (+0,30 %) liegt der Kurs bei 1,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBIKASE THERAPEUTICS INC finden Sie auf Wallstreet Online.